Oct. 11, 2017

LEO Science & Tech Hub Announces a Collaboration with Elektrofi for Formulation Technology to Improve Dermatological Drug Delivery

LEO Science & Tech Hub, today announced a collaboration agreement with Elektrofi, a Cambridge-based biotechnology company focused on drug delivery innovations, to explore advanced formulation technology for dermatological drug delivery. “We are excited to announce this collaboration with Elektrofi to explore its innovative Elektroject™ process technology to increase our options in subcutaneous delivery of antibodies” […]

LEO Science & Tech Hub, today announced a collaboration agreement with Elektrofi, a Cambridge-based biotechnology company focused on drug delivery innovations, to explore advanced formulation technology for dermatological drug delivery.

“We are excited to announce this collaboration with Elektrofi to explore its innovative Elektroject™ process technology to increase our options in subcutaneous delivery of antibodies” said Michael Sierra, Ph.D., VP of LEO Science & Tech Hub. “Developing therapeutic solutions that are not only safe and effective but also convenient for patients with skin diseases is critical to improving patient experience and outcomes, which is a goal the Hub strives to achieve.”

Elektrofi leverages a novel therapeutic microparticle suspension system (Elektroject™) to engineer high-concentration, low-viscosity antibody formulations. While many antibody formulations become virtually unusable at high concentrations due to high viscosity, Elektroject™ suspensions result in antibody concentrations that are more than 15x the typically administered concentration without exceeding viscosity limits. This enables healthcare professionals to subcutaneously administer high doses of antibody-based therapies in a relatively small volume within seconds.

“We want to create a paradigm shift in drug delivery to dramatically improve the lives of patients,” said Jason Norris, Co-Founder of Elektrofi. “LEO Science & Tech Hub is a leader in accelerating precision medicine in dermatology, and we are delighted to enter this collaboration which will combine Elektrofi’s work in transforming drug delivery with the Hub’s expertise in dermatology.”

Please read the full press release on the following link.

 

News from the hub

Dec. 2018 12 AID, HMI, and LEO Science & Tech Hub announce winners of Hacking Dermatology

Advancing Innovation in Dermatology (AID), Hacking Medicine Institute (HMi), and LEO Science & Tech Hub, the Boston-based R&D innovation unit of LEO Pharma, officially announce the final winners of Hacking Dermatology. Awardees include Lucid, a personalized and automated home patch testing solution, RxThat, an online prescription marketplace and management application, and MatchLab, a skin-image analysis […]

Read more
Oct. 2018 24 LEO Science & Tech Hub Partners with Wearifi and Northwestern University to Develop Wearable Device for Dermatology Research

CAMBRIDGE, Mass.–(BUSINESS WIRE)–LEO Science & Tech Hub, the Boston-based R&D innovation unit of LEO Pharma, announced today that they will partner with Wearifi Inc. and the Center for Bio-Integrated Electronics at Northwestern University to investigate the clinical potential of next-generation wearable electronics in dermatology research. Wearifi designs and develops the world’s smallest, battery-free wearable device. The collaboration […]

Read more